References
- Creech OJ, Jr, Krementz ET, Ryan RF, Winbald JN. Chemtherapy of cancer: Regional perfusion utilizing an extracorporal circuit. Ann Surg 1958; 148: 616–632
- Di Filippo F, Cavaliere F, Garinei R, et al. TNFα-based isolated hyperthermic limb perfusion (HILP) in the treatment of limb recurrent melanoma: Update 16 years after its first clinical application. J Chemother 2004; 16(Suppl. 5)62–65
- Hohenberger W. Isolation perfusion for malignant melanomas: Established facts and parameters to be clarified. Progress in regional cancer therapy, R Jakesz, H Rainer. Springer, Berlin, Heidelberg, New York 1990; 182
- Knorr C, Meyer T, Janssen T, Goehl J, Hohenberger W. Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience with 101 patients. Eur J Surg Oncol 2006; 32(2)224–227
- Meyer T, Göhl J, Haas C, Hohenberger W. Hyperthermic isolated limb perfusion – 23 years’ experience and improvement of results by modification of technique. Onkologie 1998; 21: 198–202
- Tonak J, Hohenberger W, Gohl J. Hyperthermic isolation perfusion of the extremities in malignant melanomas and soft tissue sarcomas. Chirurg 1984; 55(8)499–504
- Van Geel AN, van Wijk J, Wieberdink J. Functional morbidity after regional isolated perfusion of the limb for melanoma. Cancer 1989; 63(6)1092–1096
- Vrouenrates BC, Eggermont AM, Klaase JM, et al. Long-term neuropathy after regional isolated pefusion with meplhalan for melanoma of the limbs. Eur J Surg Oncol 1994; 20(6)681–685
- Vrouenrates BC, in’t Veld GJ, Nieweg OE, et al. Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan. Eur J Surg Oncol 1999; 25(5)503–508
- Meyer T, Merkel S, Göhl J, Hohenberger W. Lymph node dissection for clinically evident lymph node metastases of malignant melanoma. Eur J Surg Oncol 2002; 28: 424–430
- Olieman AF, Koops HS, et al. Functional morbidity of hyperthermic isolated regional perfusion of the extremities. Ann Surg Oncol 1994; 1(5)382–388
- Koops HS, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998; 16: 2906–2912
- Kapma MR, Vrouenrates BC, Nieweg OE, et al. Major amputation for intractable extremity melanoma after failure of isolated limb perfusion. Eur J Surg Oncol 2005; 31(1)95–99